Investment Rating - The report assigns an IPO-specific rating of 6.1, based on various criteria including company operations, industry outlook, valuation, and market sentiment [6][8]. Core Insights - The company, Heng Rui Pharmaceutical, is a leading innovative pharmaceutical enterprise rooted in China, with projected revenues of 27.985 billion RMB (+22.6%) and a net profit of 6.337 billion RMB (+47.3%) for 2024. The gross margin is expected to improve by 1.6 percentage points to 86.2% [1]. - The core growth driver is the revenue from innovative drugs, which is expected to increase from 38.1% of total revenue in 2022 to 46.3% in 2024, supported by key products like PD-L1&TGF-β and HER2ADC [1]. - The global pharmaceutical market is projected to grow from $1,472.3 billion in 2023 to $1,938.7 billion by 2028, with a CAGR of 5.7%. The Chinese pharmaceutical market is expected to grow from 1,618.3 billion RMB in 2023 to 2,342.0 billion RMB by 2028, with a CAGR of 7.7% [2]. - The company has a strong R&D capability, with an investment of 8.2 billion RMB in 2024, representing 29.4% of total revenue, and cumulative R&D investment exceeding 44 billion RMB [3]. - The company has a robust commercialization capability with a sales and marketing team of approximately 9,000, covering over 22,000 hospitals and 200,000 retail pharmacies in China [4]. Company Overview - Heng Rui Pharmaceutical is positioned as a global leader in innovative pharmaceuticals, focusing on unmet medical needs across various therapeutic areas, including oncology, metabolic and cardiovascular diseases, immunology, and neuroscience [3]. - The company has over 110 commercialized drugs, including 19 new molecular entities and four other innovative drugs [3]. - The financial health of the company is strong, with a debt-to-asset ratio of 8% and no interest-bearing debt, allowing for sustainable R&D investments [4].